Roivant Sciences (ROIV) Stock Analysis

What Roivant Sciences does

Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.

Key metrics

ETFs linked to ROIV

Broad-market and Healthcare sector ETFs an investor holding Roivant Sciences is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ROIV fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Roivant Sciences?

Roivant Sciences trades under the ticker ROIV on NASDAQ.

Which exchange is ROIV listed on?

ROIV is listed on NASDAQ.

What sector does Roivant Sciences operate in?

Roivant Sciences is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ROIV in a portfolio?

PortView shows ROIV's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.